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The CRISPR/Cas Adaptive Immune System of Pseudomonas
aeruginosa Mediates Resistance to Naturally Occurring and Engineered
Phages
Kyle C. Cady,a Joe Bondy-Denomy,b Gary E. Heussler,a Alan R. Davidson,b and George A. O’Toolea
Geisel School of Medicine at Dartmouth, Department of Microbiology and Immunology, Hanover, New Hampshire, USA,a and University of Toronto, Department of
Molecular Genetics and Department of Biochemistry, Toronto, Ontario, Canadab

Here we report the isolation of 6 temperate bacteriophages (phages) that are prevented from replicating within the laboratory
strain Pseudomonas aeruginosa PA14 by the endogenous CRISPR/Cas system of this microbe. These phages are only the second
identified group of naturally occurring phages demonstrated to be blocked for replication by a nonengineered CRISPR/Cas system, and our results provide the first evidence that the P. aeruginosa type I-F CRISPR/Cas system can function in phage resistance. Previous studies have highlighted the importance of the protospacer adjacent motif (PAM) and a proximal 8-nucleotide
seed sequence in mediating CRISPR/Cas-based immunity. Through engineering of a protospacer region of phage DMS3 to make
it a target of resistance by the CRISPR/Cas system and screening for mutants that escape CRISPR/Cas-mediated resistance, we
show that nucleotides within the PAM and seed sequence and across the non-seed-sequence regions are critical for the functioning of this CRISPR/Cas system. We also demonstrate that P. aeruginosa can acquire spacer content in response to lytic phage
challenge, illustrating the adaptive nature of this CRISPR/Cas system. Finally, we demonstrate that the P. aeruginosa CRISPR/
Cas system mediates a gradient of resistance to a phage based on the level of complementarity between CRISPR spacer RNA and
phage protospacer target. This work introduces a new in vivo system to study CRISPR/Cas-mediated resistance and an additional set of tools for the elucidation of CRISPR/Cas function.

C

lustered regularly interspaced short palindromic repeats
(CRISPR) are found in roughly 50% of sequenced bacterial
genomes and 90% of archaeal genomes (2, 24). CRISPR regions
are composed of multiple repeated sequences ranging from 21 to
48 bp in length separated by 26- to 72-bp spacers (1, 2). The
sequences of spacer regions are variable but are often identical to
sequences found within phages, plasmids, or other foreign DNA
(24). CRISPR loci are transcribed as one large transcript that is
processed within the identical repeat sequence into mature, small
CRISPR RNAs (crRNAs) by either CRISPR-associated (Cas) proteins alone or RNase III associated with Cas proteins (5, 11, 15).
These mature crRNAs are then complexed with subtype-specific
Cas proteins, and this complex specifically interacts with nucleotide target sequences complementary to spacer sequences (5, 14,
16, 26). Complementarity between mature crRNAs and sequences
found within phages or plasmids leads to inhibition of their replication through target nucleotide cleavage (12, 14, 25). The ability
of CRISPR/Cas systems to also incorporate DNA sequences from
newly encountered foreign DNA and subsequently resist phages
or plasmids containing these sequences has led these systems to be
referred to as bacterial adaptive immune systems (24).
Pseudomonas aeruginosa is an opportunistic pathogen of humans and animals that is capable of becoming highly antibiotic
resistant (18); thus, it has become a model for new or previously
overlooked antibacterial treatments, such as phage therapy (22).
To investigate the interplay between the P. aeruginosa CRISPR/
Cas systems and mobile genetic elements, such as phage, we previously analyzed the location, prevalence, and CRISPR content of
122 human clinical P. aeruginosa isolates (8). We found that 36%
of tested P. aeruginosa clinical isolates harbored CRISPR/Cas systems, 6% of the type I-E (Escherichia) subtype and 33% of the type
I-F (Yersinia) subtype (8). Furthermore, many CRISPR spacers
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found within these clinical strains were 100% identical to chromosomally integrating P. aeruginosa mobile genetic elements,
such as temperate phages, prophages, pathogenicity islands, and
transposons, suggesting that the P. aeruginosa CRISPR/Cas systems interact with these elements in a manner similar to that of
other characterized CRISPR/Cas systems (8). Consistent with this
idea, all of the P. aeruginosa isolates tested produced mature (processed) crRNAs, indicating the expression of both large CRISPR
transcripts and functional Cas proteins (8). However, using the
laboratory strain P. aeruginosa UCBPP-PA14 (PA14) and 6
crRNA-expressing clinical isolates harboring spacers 100% identical to those of P. aeruginosa bacteriophages DMS3, MP22, F116,
and D3, we were unable to demonstrate CRISPR/Cas-mediated
phage resistance (8). These data were particularly perplexing in
light of our previous observation that the P. aeruginosa CRISPR/
Cas system does interact with a specific protospacer sequence in
bacteriophage DMS3 to inhibit biofilm formation (7, 29).
Motivated by the paradoxical behavior of the P. aeruginosa
CRISPR/Cas system, in this work, we performed a large-scale
screen to identify phages that are inhibited by this system. To this
end, we generated a large collection of temperate phages by inducing and isolating them from diverse P. aeruginosa isolates. We then
tested their ability to infect wild-type (WT) P. aeruginosa PA14
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and an isogenic strain with its CRISPR-encoding region deleted
(the ⌬CR/cas mutant, lacking both CRISPR loci and all cas genes).
Using this alternative approach, we were able to obtain previously
uncharacterized phages whose replication is blocked by the endogenous CRISPR/Cas system. Further analysis of these new
phages and engineered derivatives of phage DMS3 have allowed
us, for the first time, to investigate phage resistance mediated by
the P. aeruginosa type I-F CRISPR/Cas system.
MATERIALS AND METHODS
Strains and media. The strains, plasmids, and primers used in this study
are listed in Table 1. P. aeruginosa strain PA14 was used in this study. P.
aeruginosa and Escherichia coli strains were routinely cultured in lysogeny
broth (LB) at 37°C. Growth media were supplemented with the following
antibiotics at the indicated concentrations: ampicillin (Ap), 150 g ml⫺1
(E. coli); gentamicin (Gm), 10 g ml⫺1 (E. coli) and 50 g ml⫺1 (P.
aeruginosa); and carbenicillin, 50 g ml⫺1 (E. coli) and 250 g ml⫺1 (P.
aeruginosa).
Plaque assay. Phage production was determined using a plaque assay,
essentially as described by Budzik et al. (6). Briefly, 200 l of WT P.
aeruginosa PA14 or mutant was added to 4 ml molten top agar (0.8%) and
poured over a prewarmed LB agar plate. Strains to be tested for phage
production were grown overnight at 37°C in LB and filter sterilized using
a 0.22-m-pore-size filter. After solidification of top agar lawns, 3 l of
serially diluted, filter-sterilized control and test lysates was spotted onto
the top agar lawn and incubated at 37°C overnight. Plaques were counted
and expressed as the number of PFU/ml.
Strain construction. Most strains and constructs were created using a
Saccharomyces cerevisiae recombineering technique described previously
(7, 21). During attempts to mutate the protospacer in phage DMS3 gene
42 (DMS3-42), we could create only three of the five mutations in a
CRISPR/Cas-intact background (see Fig. 2 and associated text for details).
The other two mutations (C253G and T255C) were constructed in the
⌬CRISPR2 (⌬C2) or ⌬csy3 mutant, which are both CRISPR/Cas-deficient
backgrounds.
CRISPR/Cas evasion screen. Phage DMS3 harboring a chromosomal
DMS3-42 T255C mutation was purified from an overnight-grown
⌬CRISPR2 mutant P. aeruginosa lysogen (SMC5364) using a 0.22-mpore-size filter. Purified T255C mutant phage (200 l lysate) and WT P.
aeruginosa PA14 (200 l) were then mixed 1:1 in 4 ml molten top agar
(0.8%) and poured over a prewarmed LB agar plate. After solidification,
LB top agar plates were incubated at 37°C overnight. A few single plaques
could be observed on each plate. Individual CRISPR/Cas evader plaques
were picked and cultured at 37°C overnight in 5 ml of liquid LB medium.
Following overnight growth, cultures were passed through a 0.22-mpore-size filter, serially diluted, and re-plaque purified on WT P. aeruginosa. This process was repeated a final time, before WT P. aeruginosa PA14
lysogenized by the escaper mutant phage was streaked out to single colonies and stored at ⫺80°C. The DMS3-42 gene was PCR amplified from
each strain and sequenced, revealing each crRNA target site mutation.
Evasion mutant phages were purified twice on lawns of WT P. aeruginosa
PA14 before having their DMS3-42 gene sequenced. In total, 43 such
evasion mutants were sequenced.
crRNA target plasmid transformation assay. A shuttle vector called
pHERD30T that replicates in both E. coli and P. aeruginosa was used to
clone predicted protospacers for the purposes of plasmid transformation
assays. Oligonucleotides (42 nucleotides [nt]) corresponding to a protospacer of interest (32 nt), along with 5 nt up- and downstream, were
synthesized. Extra bases corresponding to digested NcoI and HindIII restriction sites were added onto the synthesized oligonucleotides, such that
sticky ends were created when the oligonucleotides were annealed. After
annealing, these protospacers were ligated to pHERD30T digested with
NcoI and HindIII and transformed into strain DH5␣, and positive clones
were confirmed by sequencing. Plasmids containing protospacers matching the sequence of spacer 1 from CRISPR2 (abbreviated CR2_sp1) from
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WT DMS3 (5 mismatches), T255C (4 mismatches), and JBD18/
DMS3100% (DMS3100% is a phage mutant bearing a protospacer that is
100% complementary to the spacer portion of crRNACR2_sp1; 0 mismatches) as well as protospacers matching CR1_sp1 (from JBD25) or
CR1_sp6 (from JBD18) were isolated from E. coli using a BioBasic miniprep kit. P. aeruginosa cells with CRISPR/Cas intact (WT cells) or deficient
in CRISPR/Cas (⌬CR/cas cells) were grown in 5 ml of LB at 37°C in a
shaker for 18 h. Following growth, 1.0 ml of the culture was washed twice
in 1.0 ml 300 mM sucrose, resuspended in 100 l 300 mM sucrose, and
mixed with 300 to 400 ng of the indicated plasmid DNA. Each sample was
electroporated and recovered in 1.0 ml of LB medium for 1 h at 37°C.
Following incubation, each sample was diluted 10- and 100-fold and 100
l was plated onto a prewarmed LB plate containing 30 g/ml gentamicin. Each plate was incubated at 37°C for 18 h, and the resulting colonies
on each plate were counted and used to determine the transformation
efficiency as a function of the number of CFU per nanogram of plasmid
added to each plate. The transformation efficiency of plasmids containing
protospacers was compared to that of the empty vector for each individual
recipient strain and shown as a percentage. Three separate transformations were performed for each construct tested.
JBD phage isolation. A panel of 88 diverse Pseudomonas aeruginosa
isolates was screened for the presence of prophages, with 20 of these
strains also being used as indicator lawns. Indicators were chosen on the
basis of an initial screen with 8 previously characterized phages used to
infect all 88 strains. This group of 20 was chosen on the basis of the diverse
plaquing patterns (not shown). The prophage screening was performed
by individually treating each of the 88 strains with mitomycin C (3 g/ml)
during log-phase growth (optical density at 600 nm [OD600] ⫽ 0.5). After
3 to 4 h of treatment, lysis of the culture was apparent and chloroform was
added for 15 min to complete lysis. Debris was pelleted by centrifugation,
and the supernatant was stored at 4°C over chloroform. Lysates were then
screened against the panel of 20 P. aeruginosa indicator strains using traditional plaque assays. Plaques were picked and purified three times on
the same host.
JBD phage purification. High-titer phage lysates (1011 to 1012 PFU/
ml) were produced by soaking plates with near confluent lysis in SM
buffer (100 mM NaCl, 8 mM MgSO4, 50 mM Tris-HCl, pH 7.5, 0.01%
gelatin). Lysates from 10 plates were pooled, subjected to chloroform
treatment, and centrifuged to clear bacterial debris. The supernatant was
then treated with DNase (5 g/ml) and RNase (5 g/ml) for 1 h at room
temperature. Sodium chloride was then added to a final concentration of
1 M, and the mixture was placed on ice for 1 h. Finally, the lysate was
passed through a 0.45-m-pore-size filter, polyethylene glycol (PEG)
8000 (10%, wt/vol) was added, and the mixture was dissolved before being
placed on ice at 4°C for 16 h. The resulting suspension was centrifuged,
and the PEG pellet was resuspended with 500 l of SM buffer and chloroform extracted in an equal volume with centrifugation at 5,000 ⫻ g for
15 min at 4°C. The phage preparations were purified by equilibrium density gradient centrifugation in SM buffer-CsCl (0.74 mg/ml), performed
two times in succession. Ultracentrifugation was conducted for 24 h at
50,000 rpm at 4°C in a 75Ti rotor in a Beckman Coulter Optima L-90K
ultracentrifuge. Bands were extracted with a 16.5-gauge needle and dialyzed twice in a 1,000-times volume of SM buffer.
Transmission electron microscopy. Cesium chloride-purified phages
were negatively stained with 2% (wt/vol) uranyl acetate on 400-mesh
copper grids coated with carbon. Microscopy was conducted with an Hitachi 7000 transmission electron microscope at magnifications ranging
from ⫻150,000 to ⫻300,000.
Kⴙ efflux assays. Bacteria were grown in LB with 10 mM MgSO4 to
mid-log phase (OD600 ⫽ 0.5), and 5 ml of the culture was washed twice in
SM buffer without gelatin. Cells were placed on ice until use. To measure
efflux, cells were brought to 37°C in a water bath and a potassium selective
electrode was inserted, with measurements acquired every 5 s. CsCl-purified phage was added to the cells at a multiplicity of infection (MOI) of
10. Mock-treated cells received SM buffer treatment and were also sub-
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TABLE 1 Bacterial strains, bacteriophage, and plasmids utilized in this study
Strain, bacteriophage, or plasmid

Relevant characteristic (sequence)

Reference or source

Cloning strains
S. cerevisiae INVSc1
E. coli S17-1( pir)

MATa his3D1 leu2 trp1-289 ura3-52 MAT his3D1 leu2 trp1-289 ura3-52
thi pro hsdR negative hsdM positive ⌬recA RP4-2::Tc Mu-Km::Tn7

21
21

Bacteriophage
SMC3884
SMC5486
SMC5487
SMC5488
SMC5489
SMC5361
SMC5362
SMC5363
SMC5364

Wild-type DMS3 lysogen
⌬CR mutant JBD18 lysogen
⌬CR mutant JBD25 lysogen
⌬CR mutant JBD67 lysogen
DMS3vir mutant (no bacteria)
⌬csy3 lysogen of DMS3 with DMS3-42 C253G allele
⌬CRISPR2 lysogen of DMS3 with DMS3-42 C253G allele
⌬csy3 lysogen of DMS3 with DMS3-42 T255C allele
⌬CRISPR2 lysogen of DMS3 with DMS3-42 T255C allele

29
This study
This study
This study
This study
This study
This study
This study
This study

DMS3-42 T255C evasion mutants
SMC5429
SMC5430
SMC5431
SMC5432
SMC5433
SMC5434
SMC5391
SMC5392
SMC5393
SMC5424
SMC5394
SMC5395
SMC5396
SMC5425
SMC5397
SMC5398
SMC5399
SMC5400
SMC5426
SMC5401
SMC5402
SMC5403
SMC5404
SMC5405
SMC5406
SMC5407
SMC5408
SMC5409
SMC5410
SMC5428
SMC5411
SMC5427
SMC5412
SMC5413
SMC5414
SMC5415
SMC5416
SMC5417
SMC5418
SMC5419
SMC5420
SMC5421
SMC5422

Evasion mutant 1 T255C/A245G
Evasion mutant 2 T255C/T244C
Evasion mutant 3 T255C/A245G
Evasion mutant 4 T255C/T239G
Evasion mutant 5 T255C/G264A
Evasion mutant 6 T255C/T239A
Evasion mutant 7 T255C/A251G
Evasion mutant 8 T255C/A251G
Evasion mutant 9 T255C/A251G
Evasion mutant 10 T255C/A248G
Evasion mutant 11 T255C/A251G
Evasion mutant 12 T255C/A245G
Evasion mutant 13 T255C/G257T
Evasion mutant 14 T255C/C255T
Evasion mutant 15 T255C/A251G
Evasion mutant 16 T255C/A251G
Evasion mutant 17 T255C/A262G
Evasion mutant 18 T255C/A245G
Evasion mutant 19 T255C/A248T
Evasion mutant 20 T255C/A248G
Evasion mutant 21 T255C/A251G
Evasion mutant 22 T255C/A251G
Evasion mutant 23 T255C/A245G
Evasion mutant 24 T255C/A251G
Evasion mutant 25 T255C/A245G
Evasion mutant 26 T255C/A251G
Evasion mutant 27 T255C/A251G
Evasion mutant 28 T255C/A251G
Evasion mutant 29 T255C/G257T
Evasion mutant 30 T255C/C236A
Evasion mutant 31 T255C/T244C
Evasion mutant 32 T255C/A248G
Evasion mutant 33 T255C/G264A
Evasion mutant 34 T255C/A248G
Evasion mutant 35 T255C/G264A
Evasion mutant 36 T255C/A245G
Evasion mutant 37 T255C/A251G
Evasion mutant 38 T255C/A248G
Evasion mutant 39 T255C/A251G
Evasion mutant 40 T255C/A262G
Evasion mutant 41 T255C (no secondary mutation found)
Evasion mutant 42 T255C/A245G
Evasion mutant 43 T255C/G261A

This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
(Continued on following page)
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TABLE 1 (Continued)
Strain, bacteriophage, or plasmid

Relevant characteristic (sequence)

Reference or source

CRISPR deletions
SMC3893
SMC3895
SMC5454
SMC4279

⌬CRISPR1
⌬CRISPR2
⌬CRISPR1 ⌬CRISPR2 double mutant (cas genes intact)
⌬CRISPR region (no remaining cas genes)

29
29
This study
8

Plasmids
SMC3505
SMC5490
SMC5491
SMC5492

E. coli/pMQ70-derived vector (Carbr/Ampr)
E. coli/pMQ70 DMS3-42 target allele (Carbr/Ampr)
E. coli/pMQ70 DMS3-42 C253G target allele (Carbr/Ampr)
E. coli/pMQ70 DMS3-42 T255C target allele (Carbr/Ampr)

This study
This study
This study
This study

CRISPR1 spacer ␣ (DMS3-42)
(AACGGCCGACGCTTCTGGGTCGTCGTGAAAGT)
CRISPR2 spacer ␣ (DMS3-42)
(GACGTCTGACCAGCGAGTTGCAACGTCACCAC)
CRISPR2 spacer ␤ (DMS3-41)
(CTGGCCACCCAGGCGAAACTGGCGGCAGTGCT)
CRISPR2 spacer  (DMS3-41)
(AGTCGTTGTCCAGCGGCATCATGGGGCTGTTT)
CRISPR2 spacer ␦ (DMS3-42)
(ACTTTCACGACGACCCAGAAGCGTCGGCCGTT)
CRISPR2 spacer ε (DMS3-45)
(TCGGACACGCACGTTATGCGACTGCTGTCCAC)
CRISPR2 spacer  (DMS3-42)
(ACTTTCACGACGACCCAGAAGCGTCGGCCGTT)
CRISPR2 spacer ␥ (DMS3-41)
(GGAACAGGCACAAGCGACAGTATCCCGATTCT)
CRISPR2 spacer  (DMS3-42)
(GACGTCTGACCAGCGAGTTGCAACGTCACCAC)

This study

Spacer integration screen
SMC5467
SMC5457
SMC5460
SMC5465
SMC5464
SMC5466
SMC5463
SMC5461
SMC5459

jected to the same protocol in parallel to control for spontaneous leakage
of ions from cells. All assays were performed in triplicate. Results of single
representative experiments are shown in the figures.
Spacer integration screen. Three hundred microliters of WT P.
aeruginosa PA14 grown overnight in LB medium was coinoculated with
⬃1010 PFU of phage DMS3 vir (MOI, ⬃10 to 100) in 5 ml of fresh LB
medium overnight at 37°C. Overnight cocultures were serially diluted in
LB medium and plated onto predried LB plates before incubation at 37°C
overnight. Plates that yielded single colonies were retained and analyzed
visually for twitching motility-positive colonies (rough edges). It was
noted by eye, with a dissecting scope, and in twitching motility assays (4)
that the vast majority of colonies resistant to DMS3 vir infection had lost
type IV pilus (T4P) function, an expected finding, as we previously demonstrated that T4P is the receptor of DMS3 (6). However, a few (⬃1 to 3)
rough-edged, twitch-positive colonies were observed per plate. These colonies were repatched onto new LB plates and tested for T4P activity by
twitch assay. Following confirmation of T4P activity, both CRISPR loci
from each screen candidate were PCR amplified and sequenced.
Nucleotide sequence accession numbers. The full genome sequences
of JBD18, JBD25, and JBD67 are available in the NCBI database under
accession numbers JX495041, JX495042, and JX495043, respectively.

RESULTS

The replication of six different temperate phages is inhibited by
the P. aeruginosa type I-F CRISPR/Cas system. A panel of 88
clinical and environmental isolates of P. aeruginosa was treated
with mitomycin C to induce prophages, the resulting cell lysates
were spotted on lawns of 20 diverse P. aeruginosa indicator strains,
and any observed plaques were subsequently purified. Approxi-
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This study
This study
This study
This study
This study
This study
This study
This study

mately 60 of the isolated temperate phages were able to form
plaques on strain P. aeruginosa PA14. However, 30 phage isolates
could generate plaques on other P. aeruginosa isolates in our collection but were unable to develop plaques on P. aeruginosa PA14.
To assess the possible role of CRISPR/Cas-mediated immunity
in preventing these phages from forming plaques on P. aeruginosa
PA14, we assessed the ability of this collection of phages to form
plaques on a P. aeruginosa PA14 strain lacking a functional
CRISPR/Cas system (the ⌬CR/cas mutant) (8). Six of these 30
phages (designated JBD18, JBD25, JBD37, JBD54, JBD55, and
JBD67; see Fig. 1A for electron microscopy images of selected
phages) were able to form plaques on the P. aeruginosa PA14 ⌬CR/
cas strain but not on WT P. aeruginosa PA14 (Fig. 1B; compare the
leftmost and rightmost panels). Upon generation of high-titer lysates of these six phages by growth on the ⌬CR/cas mutant, we
observed 107- to 109-fold decreases in the efficiency of plaquing
(EOP) on WT compared to that on the ⌬CR/cas mutant. These
data strongly imply that the CRISPR/Cas system in the WT P.
aeruginosa PA14 strain drastically inhibits the growth of these
phages.
If resistance to the JBD phages was mediated by a CRISPR/Cas
system, we would predict that these phages, while unable to replicate, should still be capable of injecting their DNA into the host.
To test this idea, K⫹ efflux assays were conducted to quantify the
phage genome entry kinetics of one of these phages, JBD18. This
efflux assay directly measures the increase in extracellular K⫹ ions
that occurs as a result of cytoplasmic ion leakage as the phage
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FIG 1 Isolation of bacteriophage blocked for replication by the native CRISPR/Cas system of P. aeruginosa. (A) Representative negative-stained images of
bacteriophages JBD18, JBD25, and JBD67 obtained using transmission electron microscopy. All three bacteriophages display the head and noncontractile tail
characteristic of the double-stranded DNA viral family Siphoviridae. (B) Ability of bacteriophages DMS3, JBD18, JBD25, and JBD67 to replicate on WT P.
aeruginosa PA14 and strains lacking the crRNA encoding the CRISPR1 (the ⌬CRISPR1 strain) or CRISPR2 (the ⌬CRISPR2 strain) region or both CRISPR loci
(the ⌬CRISPR1/2 strain). Serial 10-fold dilutions of bacteriophage lysates are shown by spot titration onto top agar lawns of the indicated P. aeruginosa strains.
The presence of plaques indicates that the denoted strain can no longer mediate resistance to that bacteriophage. Bacteriophages JBD18 and JBD67 are unable to
plaque on strains harboring functional CRISPR1 and CRISPR2, while JBD25 is blocked for replication only by strains with CRISPR1. (C) A K⫹ efflux assay was
performed using phage JBD18 to infect WT, ⌬CR/cas, and ⌬pilA P. aeruginosa strains to demonstrate that phage DNA is still injected in WT P. aeruginosa PA14.
(D) Diagram of the CRISPR and cas genes found in P. aeruginosa PA14. CRISPR spacer content that is 100% identical over all 32 nucleotides to a region of
bacteriophage JBD18 is indicated with spotted boxes, while those identical to regions of JBD25 and JBD67 are depicted in hashes and dark gray, respectively.
CRISPR1 and CRISPR2 are thought to be encoded on opposing DNA strands and are numbered according to convention. (E) Candidate CRISPR spacers that
likely interact with bacteriophages JBD18, JBD25, and JBD67 shown pictorially in panel D.

genome passes through the inner bacterial membrane (3). JBD18
infection resulted in the same kinetics and magnitude of K⫹ ion
efflux from the WT and ⌬CR/cas strains (Fig. 1C), demonstrating
that the JBD18 genome is able to enter WT cells at a normal rate.
In contrast to the WT strain, infection of a ⌬pilA mutant, which is
resistant to JBD18 because it lacks the type IV pilus required for
cell surface adsorption of this phage (6), resulted in little K⫹ efflux. This result confirms that the observed K⫹ efflux requires
attachment of phage to cells and that mutating the CRISPR/Cas
system does not alter injection kinetics.
To confirm the requirement of cas genes for the apparent
CRISPR/Cas system-mediated inhibition of the phages under investigation here, strains containing single gene deletions of each of
the P. aeruginosa PA14 cas genes were assayed. As shown in Table
2 (first 3 rows), deletion of any of the cas genes, with the exception
of cas1, resulted in sensitivity to infection by JBD18, JBD25, and
JBD67. The absence of an effect for the ⌬cas1 strain was expected,
as the Cas1 protein is believed to play a role in the acquisition of
new spacers but not in CRISPR-mediated interference (1, 27, 29).
Deletions of cas3, csy1, csy2, csy3, and csy4 in P. aeruginosa PA14
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have been shown to reduce or eliminate crRNA accumulation,
while ⌬cas1 strains display normal levels of processed crRNA (7).
Sequencing the genomes of JBD18, JBD25, and JBD67 reveals functional protospacer sequences. To further elucidate the
mechanism by which the phages identified here were targeted by
the CRISPR/Cas system, we sequenced the genomes of three of
these phages (JBD18, JBD25, and JBD67). As shown in Fig. 1D, P.
aeruginosa PA14 possesses two different CRISPR loci, designated
CRISPR1 and CRISPR2, with the cas genes located between the
CRISPR loci (29). Phage JBD18 contains regions with 100%
matches to spacer 6 in the CRISPR1 locus (CR1_sp6) and spacers
1 and 2 in the CRISPR2 locus (CR2_sp1, and CR2_sp2, respectively) (Fig. 1D and E). Importantly, these putative protospacers
also display the required protospacer adjacent motif (PAM),
which is GG in the type I-F CRISPR/Cas system found in P. aeruginosa PA14 (19). JBD67 displays the same putative protospacers as
JBD18, with the exception of a single mismatch with CR2_sp2,
where the A highlighted in bold in Fig. 1E is a G. JBD25 possesses
only one predicted spacer match to CR1_sp1, and the PAM is also
present. Plaque assays showed that deletion of either CRISPR1
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TABLE 2 Summary of results of plaque assays with P. aeruginosa PA14 CRISPR/cas mutantsa
Genotypeb
Phage

WT

⌬CR/cas

⌬CR1

⌬CR2

⌬cas1

⌬cas3

⌬csy1

⌬csy2

⌬csy3

⌬csy4

JBD18
JBD25
JBD67
WT DMS3
DMS3 C253G
DMS3 T255C
DMS3100%

⫺
⫺
⫺
⫹
⫺

⫹
⫹
⫹
⫹
⫹
⫹
⫹

⫺
⫹
⫺
⫹
⫺

⫺
⫺
⫺
⫹
⫹
⫹
⫹

⫺
⫺
⫺
⫹
⫺

⫹
⫹
⫹
⫹
⫹
⫹
⫹

⫹
⫹
⫹
⫹
⫹
⫹
⫹

⫹
⫹
⫹
⫹
⫹
⫹
⫹

⫹
⫹
⫹
⫹
⫹
⫹
⫹

⫹
⫹
⫹
⫹
⫹
⫹
⫹

a
b

Plaque assays conducted with the indicated phages used to infect lawns of WT or various mutant strains.
⫹, formation of plaques (EOP, 1 relative to ⌬CR/cas); -, reduced plaquing efficiency with a ⬎104-fold reduction; ⫺, reduced plaquing efficiency with a ⬎106-fold reduction.

(⌬CRISPR1 strain) or CRISPR2 (⌬CRISPR2 strain) alone did not
alleviate the inhibition of JBD18 and JBD67, whereas JBD25 was
not inhibited in the ⌬CRISPR1 strain (Fig. 1B). These results are
consistent with the protospacer matches found in the genomes of
these phages, as outlined above.
To demonstrate that the protospacers found in JBD18, JBD25,
and JBD67 were authentic targets of the PA14 CRISPR/Cas system, the putative protospacer sequences and PAMs from each
phage genome were synthesized and cloned into a high-copynumber shuttle vector capable of replication in E. coli and P.
aeruginosa. The protospacer-containing plasmids or the vector
with no insert was electroporated into WT P. aeruginosa PA14 or
the ⌬CR/cas strain, and transformation efficiencies were calculated. The plasmid containing the CR2_sp1 protospacer transformed WT P. aeruginosa PA14 with less than 0.1% of the efficiency of the empty vector, but no difference in transformation
efficiency was observed in the ⌬CR/cas strain (Fig. 2). Similarly,

FIG 2 CRISPR/Cas-dependent replication of plasmids harboring protospacer
sequences. The transformation efficiency of plasmids harboring no protospacer (vector) or the protospacer is indicated on the axis of the graph in the
presence or absence of the CRISPR/Cas system. The transformation efficiency
of each spacer-bearing plasmid was quantified relative to the transformation
efficiency of the empty vector introduced into the same strain. Transformations were performed by electroporation as described in Materials and Methods. The CR2_sp1 (JBD18) protospacer sequence is identical to that of
DMS3100%.
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transformation of WT P. aeruginosa PA14 by plasmids containing
either the CR1_sp1 or CR1_sp6 protospacer was reduced by
ⱖ80% compared to that achieved by the empty vector (Fig. 2). In
contrast, no reduction of transformation efficiency was observed
for these plasmids when they were introduced into the ⌬CR/cas
strain. Although the magnitude of the reduction in transformation efficiency caused by the action of the CRISPR/Cas system
varied depending on the particular protospacer being tested, these
results clearly demonstrate that the P. aeruginosa PA14 CRISPR/
Cas system is active against protospacers present in phages that are
inhibited by the system. Thus, the presence of these protospacers
is likely the source of the vulnerability of these phages to the
CRISPR/Cas system.
In summary, the results described above demonstrate for the
first time that the type I-F CRISPR/Cas system of P. aeruginosa
functions in a manner similar to that of other CRISPR/Cas systems to inhibit the replication of phages bearing matches to spacers contained within the CRISPR loci.
Engineering of DMS3 variants blocked for infection by
CRISPR/Cas system. We previously demonstrated that P. aeruginosa crRNACR2_sp1 (crRNA encoded by CR2_sp1) interacts with a
protospacer in phage DMS3 gene 42 (DMS3-42) to inhibit biofilm
formation in DMS3 lysogens (7, 29). However, we observed no
resistance mediated by this crRNA interaction with phage DMS3
(8, 29). Since the transformation efficiency of a plasmid bearing
the CR2_sp1 protospacer from JBD18, which is 100% identical to
crRNACR2_sp1, was strongly inhibited by the P. aeruginosa PA14
CRISPR/Cas system (Fig. 2), we hypothesized that the lack of inhibition of DMS3 by the CRISPR/Cas system might be due to the
lack of complementarity between crRNACR2_sp1 and the DMS3-42
protospacer (Fig. 3A).
To test the effect of creating complementarity between
crRNACR2_sp1 and the DMS3 protospacer, single-base-pair mutant alleles of DMS3 were created (denoted by thick black arrows
in Fig. 3A). Strikingly, the single nucleotide changes in the DMS3
genome, C253G or T255C, led to strong inhibition of DMS3 replication by the CRISPR/Cas system, even though 4 mismatches
with crRNACR2_sp1 remained (Fig. 3B). Conversely, other changes
in the protospacer (C237G, G240C, and C258G) had no effect on
the ability of DMS3 to replicate in WT P. aeruginosa PA14 (not
shown). These data indicate that for crRNACR2_sp1 to mediate resistance to phage DMS3, complementarity between the crRNA
and the protospacer at nucleotide position 253 or 255 but not at
positions 237, 240, and 258 is required. Like phage JBD18, K⫹
efflux assays demonstrated that this resistance was manifested af-

jb.asm.org 5733

Cady et al.

FIG 3 Engineering of DMS3 variants blocked for infection by the CRISPR/Cas system. (A) Model of Csy-crRNACR2_sp1 riboprotein complex (comp.) interacting
with the DMS3-42 target sequence. The model is based on previous work performed by the Doudna group (15, 26). Csy proteins (various shades of gray) are
shown coating crRNACR2_sp1, while lines denote Watson-Crick base pairing between crRNACR2_sp1 and its bacteriophage target sequence in gene 42 of phage
DMS3 (DMS3-42). The crRNA seed sequence and bacteriophage PAM, which is thought to be critical for crRNA-target interaction, are shown within shadowed
boxes. Thick black arrows show the location of mutant alleles C253G and T255C; note their proximity but exclusion from seed and PAM sequences. (B) Ability
of bacteriophage DMS3 harboring WT, C253G, and T255C DMS3-42 alleles to infect WT (CRISPR/Cas-intact) and ⌬CR (CRISPR/Cas-deficient) bacteria. WT
DMS3 can readily replicate in the presence and absence of the CRISPR/Cas system (compare the tops row in both panels). Bacteriophages harboring either the
DMS3-42 C253G or the DMS3-42 T255C allele purified from two different genetic backgrounds are not able to replicate in CRISPR/Cas-intact bacteria (compare
the bottom four rows of each panel). (C and D) Ability of bacteriophages harboring C253G (C) and T255C (D) alleles to inject their genomic DNA into WT
(CRISPR/Cas intact) or the ⌬CR/cas (CRISPR/Cas-deficient) or ⌬pilA (lacking bacteriophage receptor) mutant determined by the K⫹ efflux assay.

ter genome injection (Fig. 3C and D), as would be expected for
resistance mediated by the CRISPR/Cas system.
To further investigate the effects of the point mutations described above, the transformation efficiencies of plasmids harboring the WT DMS3 CR2_sp1 protospacer (5 mismatches) and the
T255C mutant protospacer (4 mismatches) were compared. As
shown in Fig. 2 (rightmost two sets of bars), the presence of the
T255C mutation in the DMS3 protospacer sequence caused an
80-fold decrease in the transformation efficiency of P. aeruginosa
PA14 compared to that achieved with the plasmid bearing the WT
DMS3 protospacer sequence. This difference was not observed
when the same plasmids were used to transform the PA14 ⌬CR/
cas mutant strain. These data show that the same point mutation
that led to a dramatic CRISPR/Cas-mediated inhibition of phage
DMS3 replication (Fig. 3) also imparted a reduction in transformation efficiency similar in magnitude to the reductions described for the JBD phage-derived sequences.
To further enhance our understanding of the specificity requirements of this CRISPR/Cas system for the protospacer target
sequence, we undertook a screen to identify phage mutants that
evade targeting. We plated high titers of phage DMS3 harboring
the DMS3-42 T255C allele (MOI, ⬃100) onto WT (CRISPR/Casintact) P. aeruginosa PA14 lawns. As was previously observed in E.
coli and Streptococcus thermophilus (1, 5), this procedure allowed
us to isolate mutant phages with the ability to escape the CRISPR/
Cas system. Consistent with the previous studies, such escape mutants (42 out 43 sequenced) were found to possess single base

5734

jb.asm.org

mutations within the CR2_sp1 protospacer or PAM in DMS3-42
(Fig. 4). We could not identify the 43rd mutation, which presumably maps outside the DMS3-42 gene.
Mismatches between crRNA and protospacer can result in
intermediate resistance. In analyzing the effects of point mutations in the DMS3 CR2_sp1 protospacer, we created a phage mutant, which we refer to as DMS3100%, bearing a protospacer that is
100% complementary to the spacer portion of crRNACR2_sp1. Interestingly, while the plaquing efficiency of the DMS3 mutant
bearing the T255C mutation was inhibited by ⬃104-fold when
plated on P. aeruginosa PA14, that of the DMS3100% phage was
inhibited by greater than 106-fold (Table 2).
This discrepancy was even more apparent when experiments
were performed at 30°C, where the plaquing efficiency of DMS3
T255C was reduced by only ⬃100-fold compared to that for WT
DMS3, while the plaquing efficiency of DMS3100% was still reduced by ⬎106-fold (Fig. 5A). The DMS3 C253G mutant also
displayed at least a 1,000-fold higher plaquing efficiency on P.
aeruginosa PA14 at 30°C than DMS3100% (Fig. 5C and inset).
These data imply that although this CRISPR/Cas system still functions in the face of crRNA mismatches, the efficiency of the system
may be reduced. This finding was mirrored by plasmid transformation assays with P. aeruginosa PA14, where the transformation
efficiency of a plasmid bearing a protospacer with 100% identity
to CR2_sp1 was 10-fold lower than that for the one bearing the
T255C mutant protospacer, which still had four mismatches with
the crRNA (Fig. 2).
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FIG 4 Isolation and characterization of bacteriophages that have evaded
CRISPR/Cas-mediated resistance. (A) Diagram showing crRNACR2_sp1 (bottom) interacting with the bacteriophage DMS3-42 T255 target allele (top). The
crRNA seed (26) and bacteriophage PAM (19) sequences are boxed to simplify
the orientation and interpretation of results. Each letter depicted above an
arrow indicates an individual CRISPR/Cas evasion mutation harboring the
given single-base-pair mutation. (B) Susceptibility of bacterial strains with
intact CRISPR/Cas (WT) and deficient in CRISPR/Cas (⌬CR/cas) to bacteriophage DMS3 harboring the indicated DMS3-42 alleles.

It should be noted that we do not have an explanation for the
weaker CRISPR/Cas system effect in plaquing assays performed at
30°C. The results in plasmid transformation efficiency assays were
not affected by temperature (data not shown), suggesting that the

CRISPR/Cas functions with similar efficiency at the two temperatures. We speculate that phage replication may be more efficient
at a lower temperature, and thus, evasion of the CRISPR/Cas system occurs more readily.
The P. aeruginosa type I-F CRISPR/Cas system is adaptive to
lytic phage attack. In the context of a bacterial immune system, it
is critical that bacteria acquire new spacer content in response to
phage challenge (2, 24). To date, only the S. thermophilus CRISPR/
Cas system has been shown to undergo spacer acquisition in response to phage attack using a native CRISPR/Cas system (1),
although other systems have demonstrated spacer acquisition under engineered conditions, such as plasmid overexpression or
misregulation of cas genes (10, 23, 28).
To analyze CRISPR adaptation in P. aeruginosa, we created a
nonreverting lytic mutant (vir mutant) of phage DMS3 (DMS3
vir). This lytic variant was made by deleting the nucleotides that
encode the first 76 amino acids of the 185-amino-acid c repressor
protein, which is required for lysogeny (13). A lytic phage similar
to DMS3 that completely lacked its c repressor was previously
isolated (17). Figure 6A illustrates that addition of increasing levels of DMS3 vir to WT P. aeruginosa cultures results in a concurrent rise in bacterial lysis, clearly demonstrating the lytic activity of
DMS3 vir.
Although it was possible to isolate small numbers of DMS3
vir-resistant colonies from these lysed cultures by plating the lysate on LB agar, most resistant strains carried mutations that resulted in loss of type IV pilus (T4P) function. T4P is the known
receptor for DMS3 and many other P. aeruginosa phages (9). The
T4P of P. aeruginosa can be extended and retracted to move the
bacteria across a hard agar surface in a process known as twitching
motility (4). P. aeruginosa twitching-deficient colonies have a
smooth edge due to their inability to undergo twitching motility at
the agar-colony edge (Fig. 6B) and are unable to produce a motility zone in the standard plate-based twitching motility assay (4).

FIG 5 Effect of temperature on CRISPR/Cas-mediated inhibition of bacteriophage replication. Plaque assays showing the replication of WT DMS3, DMS3
C253G, DMS3 T255C, DMS3100%, and JBD18 in the presence (A, C) or absence (B) of the CRISPR/Cas system at 30°C. Arrows, locations of single plaques. Phages
were spotted in 10-fold serial dilutions.
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FIG 6 Screen to identify integration of new bacteriophage-derived spacer content into CRISPR. (A) Image showing greater lysis of P. aeruginosa cells as
increasing levels of lytic bacteriophage DMS3 vir are added. (B) Dissecting microscope image of twitching-negative (left) and twitching-positive (right) colony
edges. This phenotype is also visible by eye for well-grown P. aeruginosa colonies (data not shown). The majority of DMS3 vir-resistant colonies that retained T4P
function (irregularly edged colonies that were twitching motility positive) had obtained a new CRISPR spacer that provided resistance to bacteriophage DMS3
vir. (C to F) Shown are the newly inserted spacers carried in each strain, with the WT and the ⌬CRISPR/cas mutant included as controls (C). The sequence of the
inserted spacers (D), their putative target gene (E), and the target strand (F) are also indicated. All newly integrated spacers target phage regions with an intact
GG PAM motif. (G) Susceptibility of each strain to bacteriophage DMS3 vir. Each spot marks a 10-fold dilution of the DMS3 vir lysate from left to right. Taken
together, these data demonstrate that the P. aeruginosa CRISPR/Cas system can integrate new spacer content conferring resistance in response to bacteriophage
challenge.

This loss of T4P production was assessed for the DMS3 vir-resistant strains first by colony morphology and then via the standard
plate-based twitching motility assay.
A small number of strains resistant to DMS3 vir infection
(⬍1%) retained T4P function, as judged by the colony assay. The
CRISPR loci of nine confirmed twitch-positive, DMS3 vir-resistant isolates (Fig. 6G) from this selection were sequenced (Table
1), revealing the insertion of new spacer sequences into CRISPR1
or CRISPR2, and these spacers were 100% complementary to regions of phage DMS3 (Fig. 6C to E). Importantly, each of the
newly inserted spacer sequences is complementary to a DMS3
protospacer with a conserved GG dinucleotide PAM sequence.
The newly integrated CRISPR spacers provided resistance to
phage DMS3 vir and are predicted to encode small crRNAs complementary to either the coding or noncoding strand of phage
DMS3 (Fig. 6F).
DISCUSSION

Here we demonstrate that the type I-F CRISPR/Cas system, like
the type I-E (E. coli) (5) and type II-B (S. thermophilus) (1)
CRISPR/Cas systems, can provide sequence-specific and adaptive
resistance to phage challenge. Using a diverse temperate phage
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library isolated from environmental and clinical strains of P.
aeruginosa, we isolated six phages that are natively targeted and
blocked for infection by the endogenous P. aeruginosa CRISPR/
Cas system. In addition, we used single nucleotide point mutations to engineer a phage which was not susceptible to this
CRISPR/Cas system to become resisted. Lastly, we devised a
screening technique to observe CRISPR spacer acquisition in response to phage challenge. This work provides the first evidence
for an endogenously functioning CRISPR/Cas adaptive immune
system in P. aeruginosa and has opened up a new in vivo system for
future study. This is an important advance because many key
structural and in vitro functional studies on Cas proteins have
been performed on the P. aeruginosa PA14 type I-F system (15,
26, 27).
Our work has provided insight into the protospacer sequence
requirements of this type I-F system. In engineering phage DMS3
to be targeted by the CRISPR/Cas system (Fig. 3) and in selecting
for escape mutants of DMS3 (Fig. 4), we found that mismatches in
nucleotide positions across the whole protospacer region and
PAM led to abrogation of targeting (Fig. 4B). These results contrast to those of other studies of the type I-E CRISPR/Cas system,
where only mismatches within the PAM and an 8-nucleotide re-
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gion adjacent to the PAM, designated the seed, affected targeting
by the CRISPR/Cas system (20). Our identification of escape
phages with mutations in the PAM provides the first experimental
evidence that the conserved GG dinucleotide PAM of the type I-F
CRISPR/Cas system is required for phage targeting in vivo, as has
been observed in other CRISPR/Cas systems (19, 20). Similar to
previous work (20), we found that a 1-nucleotide gap at position 6
of the seed sequence could be tolerated. Overall, these data support the importance of the crRNA seed sequence and phage PAM
but highlight the critical importance of regions external to the seed
sequence and PAMs for crRNA-mediated resistance.
Using the plasmid transformation efficiency assay, we demonstrated that protospacers with 100% identity to the CR1_sp1,
CR1_sp6, and CR2_sp1 spacers are targeted by the system. Plasmids containing these sequences displayed reduced transformation efficiencies. Surprisingly, the degree of inhibition of transformation varied widely depending on the protospacer tested. For
example, the CR1_sp6 protospacer from JBD18 and JBD67, when
placed on a plasmid, resulted in only a 5-fold inhibition of transformation, while the CR2_sp1 protospacer from JBD18 and
JBD67 (or DMS3100%) caused a 1,000-fold inhibition. Surprisingly, the replication of phages JBD18 and JBD67, which contained the CR1_sp6 protospacer, was still inhibited 107-fold when
plated on a strain with the CRISPR2 locus deleted. In this background, the CR1_sp6 protospacer is the only sequence in these
phages that displays any significant similarity to a CRISPR spacer;
thus, its presence in the JBD18 and JBD67 genomes is almost
certainly the cause of the poor plating efficiency of these phages,
despite the weak effect of this protospacer in the transformation
assay. The various effects on transformation efficiency of different
protospacers are difficult to explain, but these differences were
observed consistently and likely reflect subtleties in the functioning of this system that are yet to be elucidated.
Through engineering of phage DMS3, we found that the protospacer within the DMS3-42 gene could be efficiently targeted by
the CRISPR/Cas system, even when it possessed 4 mismatches
with crRNACR2_sp1. However, the DMS3100% phage, which
matches crRNACR2_sp1 with 100% identity, was clearly targeted
more efficiently than phage containing mismatches, as was observed most noticeably in the plaquing assays performed at 30°C
(Fig. 5). This decreased targeting of the mismatched protospacer
was also reflected in the plasmid transformation assay, where the
protospacer with no mismatches caused a 10-fold greater decrease
in transformation efficiency than a protospacer with mismatches
(Fig. 2). These data show that the CRISPR/Cas system is not all or
nothing and that the degree of complementarity between the
crRNA and protospacer sequences can affect the efficiency with
which the system operates.
Consistent with a gradient of effectiveness for the P. aeruginosa
CRISPR/Cas system, the WT DMS3-42 protospacer, which has 5
mismatches with crRNACR2_sp1, does not cause resistance to phage
DMS3. However, we have previously shown that this protospacer
does interact with the CRISPR/Cas system to inhibit biofilm formation in P. aeruginosa PA14 when it contains a DMS3 prophage.
These data suggest that the effect on biofilm formation (in the
absence of detectable resistance) may reflect a weak or altered
interaction between the CRISPR/Cas system and phage DMS3.
Previously, we identified, sequenced, and assayed the function
of CRISPR/Cas systems found in a diverse array of clinical P.
aeruginosa strains (8). In that study, we were unable to detect
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CRISPR/Cas-mediated resistance to phages DMS3, MP22, F116,
and D3, even though the strains on which they were tested (P.
aeruginosa PA14 and 6 other clinical isolates) were shown to express fully processed crRNA and harbor spacers 100% identical to
the tested phages (8). In the work described here, by screening a
large collection of temperate phages isolated from diverse P.
aeruginosa strains, we identified a small group of phages that are
inhibited by the CRISPR/Cas system of P. aeruginosa PA14. At this
point, it is unclear why some phages are inhibited by the CRISPR/
Cas system, while others possessing protospacers and intact PAM
sequences, which would thus be predicted to be targeted, are not
inhibited. It is possible that crRNA molecules complementary to
certain spacers do not accumulate to levels high enough to be
equally effective or lack activity for other reasons. Additionally,
some phages may possess mechanisms for overcoming the
CRISPR/Cas system, though no such mechanisms have yet been
described.
To date, only the S. thermophilus CRISPR/Cas system has been
shown to undergo spacer acquisition in response to phage attack
using a native CRISPR/Cas system (1), although other systems
have been shown to acquire spacer content under engineered conditions, such as plasmid overexpression or misregulation of cas
genes (23, 28). Using a nonreverting lytic mutant of phage DMS3,
we demonstrate that in P. aeruginosa new CRISPR spacers can be
obtained through a plate-based screen. This method should drastically improve the ability to perform future CRISPR adaptation
studies. Further, this technique should be applicable to many of
the pilus-attaching phages known to infect P. aeruginosa, including those with single-stranded RNA genomes, such as the levivirus
phages PP7 and PRR1 (9).
In conclusion, this work presents an important advance for the
investigation of CRISPR/Cas in vivo function. Our results provide
the first evidence for phage and plasmid resistance by a type I-F
CRISPR/Cas system, as well as a collection of phage-crRNA interactions for future analysis. Furthermore, our demonstration of
variable effects of different protospacers in the plasmid transformation assay and the potential modulation of sensitivity to the
CRISPR/Cas system through reduction of complementarity between protospacer and crRNA highlights a potential for subtlety
in this system that has not previously been recognized.
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